Lumawan, Renielyn H.
HRN: 14-25-25 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
08/30/2024
CO-AMOXICLAV 625MG (TAB)
08/30/2024
09/06/2024
PO
625 Mg
BID
S/P NSD, Leukocytosis
Waiting Final Action
Indication: Prophylaxis Type of Infection: Reproductive Tract Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes